Brief: Helix Biopharm says trial steering committee made recommendation to initiate phase II component of LDOS002 study
21/04/2016 10:00
April 21 (Reuters) - Helix Biopharma:
* Trial Steering Committee Recommends Initiation Of Phase II
L DOS47 study in non-small cell lung cancer
* Says trial steering committee recommendation to initiate
phase II component of LDOS002 study
Source text for Eikon: urn:newsml:reuters.com:*:nMKWcg28da
Further company coverage: HBP.TO
(Bengaluru Newsroom)
(((+91 80 6749-1130; within U.S. +1 646 223 8780);))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020